Atrial fibrillation (AF) significantly elevates stroke risk, making prevention essential.
Untreated atrial fibrillation carries in approximately 3 to 5% annual risk of ischemic stroke.
Long-term and coagulation therapy decreases this risk to 1.7% with warfarin and to 1.5% with novel oral anticoagulants.
The price for lowering the risk of atrial fibrillation is an annualized rate of major bleeding of 2.75-3.43% a complication of long-term oral anticoagulation therapy.
The CHA₂DS₂-VASc score helps evaluate stroke risk based on factors: Heart failure, Hypertension, Age particularly ≥75 years Diabetes History of stroke or thromboembolism, vascular disease, Sex
Anticoagulation therapy is central to stroke prevention in AF patients.
Patients who receive DOAC‘s or vitamin K antagonists have an increased risk of bleeding with 60-100% more major bleeds in patients who receive no anticoagulation or anti-platelet therapy, respectively.
Most patients with AF have two or more risk factors for stroke, and this combination usually results in high annual risk of stroke of 1.5 to 2% per year, which justifies the use of anticoagulation.
Approximately 5 to 15% of patients with AF present with only one stroke risk factor (CHA2DS2 – VA score of one; scores range from 0 to 8 with high schools in the beginning, a greater risk of stroke).
Oral anticoagulation can prevent approximately 2/3 of strokes and patients with clinical atrial fibrillation.
Oral anticoagulation is recommended for patients with atrial fibrillation, whose annual risk of stroke is 2% or greater.
Direct Oral Anticoagulants (DOACs) are preferred for non-valvular AF.
Options: Apixaban, Rivaroxaban, Dabigatran, Edoxaban
DOACs Advantages-Fixed dosing, fewer interactions, no regular monitoring Vitamin K Antagonists Necessary for patients with mechanical heart valves or moderate-severe mitral stenosis. Requires regular INR monitoring, with a target range of 2.0-3.0.
Left Atrial Appendage Management: For those intolerant to anticoagulation: Devices: WATCHMAN, AMPLATZER Surgical closure during heart surgery
Rate Control focuses on managing heart rate without restoring sinus rhythm.
Rhythm Control aims to restore normal sinus rhythm and could reduce stroke risk. Includes cardioversion, antiarrhythmics, and ablation.
Additional Prevention Strategies
Blood Pressure Management Lipid Management Lifestyle Modifications-Smoking cessation, moderate alcohol intake or abstinence, weight management, regular exercise, and sleep apnea treatment.
Among patients with AF and intermediate risk for stroke, DOAC therapy lead to lower risk of stroke, systemic, embolism, major bleeding, or death from cardiovascular causes at 24 months than no anticoagulation (SINGLE-AF investigators).